Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide plus whole-brain simultaneous modulated accelerated radiotherapy for brain metastases
ChiCTR2100044800Phase 2Recruiting
- Sponsor
- Zhengzhou Central Hospital
- Start
- Jun 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of temozolomide in brain metastases (2 arms), sponsored by Zhengzhou Central Hospital. Primary endpoint: Intracranial progression-free survival (IPFS). Started Jun 2020; status: recruiting.
02
Drugs
temozolomide
03
Conditions
brain metastases
Beyond the preview
Go deeper on ChiCTR2100044800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044800.